Keywords: merck, co, 4th-qtr, line, estimates, net, income
Merck & Co 4th-qtr in line with estimates; net income down 23%
Article | 02 February 2004
As a result of charges and lower product sales, US drug major Merck & Co has reported a 23% decline in fourth-quarter 2003 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
